2011年 · 第44卷第10期

With the application of basic medicine, especially molecular biology in clinical medicine, especially the implementation of human genome project, the diagnosis and treatment of many human hereditary neurological diseases have brought rapid changes. In recent years, the genetic testing of epilepsy is one of the most important advances in the field of neuroscience. How significant is the genetic testing of epilepsy to clinical practice? What are its potential benefits and risks? What are the detection methods? How should these tests be used? What are the evaluation criteria for the utility of genetic testing for epilepsy? Such issues have always been a hot topic of everyone's great concern. The Genetic Committee of the International Alliance Against Epilepsy (ILAE) in 2010EpilepsiaThe programmatic report "Report of the Genetic Committee of ILAE-Genetic Testing for Epilepsy" was published for the first time, pointing the way for us.

Background and Purpose:Plasma exchange therapy has become one of the main treatment measures for various neurological diseases. Recently, the Treatment and Technology Evaluation Committee (TTA) of the American Academy of Neurology (AAN) reevaluated the therapeutic effect of plasma exchange in neurological diseases based on new research data.Method:The TTA evaluated the relevant literature review from January 1995 to September 2009, and also revised the level of evidence for diagnosis and treatment opinions in the 1996 edition of the guidelines.Conclusion:The recommendations of the new guidelines for the use of plasma exchange in neurological disorders are summarized inTable 1。